

**THE FOLLOWING DRUGS WILL BE REVIEWED AT THE  
DRUG UTILIZATION REVIEW BOARD (DURB) MEETING**

**December 15, 2015**

**Georgia Department of Community Health**

**\*This list may change at any time so please check back frequently for updates.\***

**New Drugs for Review**

Avycaz and Zerbaxa

Cholbam

Cresemba

Farydak

Ixinity and Novoeight

Movantik

Natpara

Nplate

Signifor LAR

**Non-Supplemental Rebate Classes for Review**

Antihemophilic Products

Antiinfectives, Beta Lactams – Beta-Lactamase Inhibitors and Penicillins

Antiinfectives, Beta Lactams – Intravenous Cephalosporins and Beta-Lactamase Inhibitors

Antiinfectives, Antifungals - Invasive Aspergillosis and Mucormycosis

Antiinfectives, Antimalarials

Antiinfectives, Antimycobacterials

Antiinfectives, Toxoplasmosis

Antineoplastics, Multiple Myeloma

Gastrointestinal, Bile Acid Agents

Gastrointestinal, Opioid-Induced Constipation Agents
Hematopoietics, Iron Injectables
Hormone Modifiers, Acromegaly Agents
Hormone Modifiers, Parathyroid Agents
Luteinizing-Hormone-Releasing Hormone/Gonadotropin-Releasing Hormone Agonist Analogs
Thrombopoietin Receptor Agonists
Short Bowel Syndrome
Vitamin D Analogs

**\*This list may change at any time so please check back frequently for updates.\***